News headlines about AVENUE THERAPTC (NASDAQ:ATXI) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. AVENUE THERAPTC earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.1172146767699 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
AVENUE THERAPTC (NASDAQ ATXI) opened at 6.55 on Friday. The stock’s market cap is $21.88 million. The company has a 50-day moving average price of $7.83 and a 200-day moving average price of $7.84. AVENUE THERAPTC has a 52 week low of $5.94 and a 52 week high of $8.58.
About AVENUE THERAPTC
Avenue Therapeutics, Inc is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for the management of moderate to moderately severe postoperative pain.
What are top analysts saying about AVENUE THERAPTC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AVENUE THERAPTC and related companies.